CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE


## CONTROVERSIES & UPDATES IN VASCULAR SURGERY MARRIOTT RIVE GAUCHE & CONFERENCE CENTE JANUARY 19-21 2017 PARIS, FRANCE

米

www.cacvs.org

#### Is B Mode Screening Aorta Aneurysm save LIFE!





#### **Opération VESALE 2014-2015**

Dépistage de l'anévrisme de l'aorte abdominale - Une année pour se faire dépister !





#### **Laroche Jean Pierre**

Médecin Vasculaire Hôpital Saint Éloi Montpellier. Médipôle, Avignon France





#### No conf£ict\$ of int€r€\$t with my £ink\$.

- Investigator: Bayer Healthcare, Daiichi Sankyo, Astra-Zeneca, Portola, Aloka Hitachi
- Board : Leo Pharma
- Congress Invitation : Léo Pharma, Bayer Healthcare, Almoka-Hitachi













Société française de médecine vasculaire 2007 <sup>13</sup>	France	<ul> <li>Recommandé: hommes/femmes &gt; 50 ans avec antécédents familiaux</li> <li>Recommandé: hommes fumeurs, 60-75 ans</li> <li>Proposé: hommes non fumeurs, 60-75 ans</li> <li>Proposé: femmes 60-75 ans, fumeuses et/ou hypertendues</li> <li>Proposé: après 75 ans, si bonne espérance de vie et faible comorbidité</li> </ul>	
---	--------	---	--

**Recommended:** men and women > 50 years old with family history

Recommended: smoking men, 60 to 75 years old

Proposed: men non smoking, 60 – 75 years old

Proposed: women, 60 to 75 years old, smoking and / or hypertension

Proposed : > 75 years old, men and women with good life expectancy and low co morbidity



#### **Men and Women**





#### February 2013

la pertinence de la mise en place d'un programme de dépistage des AAA en France, la HAS recommande le dépistage ciblé opportuniste unique (c'est-à-dire « qui ne sera proposé qu'une seule fois ») des AAA chez les hommes répondant aux caractéristiques suivantes :

- âge compris entre 65 et 75 ans et tabagisme chronique actuel ou passé (voir tableau synoptique);
- age compris entre 50 et 75 ans et antécédents familiaux d'AAA (voir tableau synoptique).

Cette mesure doit être accompagnée d'une prise en charge thérapeutique globale des personnes ayant été identifiées comme ayant un AAA.

Recommended: men > 50 years old with family history Recommended: smoking men, 65 to 75 years old



Opportunist screening (GP)
TARGET and UNIQUE
MEN only
NO ORGANISATION: as you want, French
Method or French Tech?



# 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases



#### Recommendations for abdominal aortic aneurysm screening

**MEN** 

WOMEN




Recommendations	Classa	Level <sup>b</sup>	Ref.c
Population screening for AAA with ultrasound:			
<ul> <li>is recommended in all men &gt;65 years of age.</li> </ul>	- 1	A	357,367
<ul> <li>may be considered in women &gt;65 years of age with history of current/past smoking.</li> </ul>	IIb	U	
<ul> <li>is not recommended in female non- smokers without familial history.</li> </ul>	III	C	
Targeted screening for AAA with ultrasound should be considered in first-degree siblings of a patient with AAA.	lla	В	338,339
Opportunistic screening for AA	A during T	TE:	
<ul> <li>should be considered in all men &gt;65 years of age.</li> </ul>	lla	В	346,347
<ul> <li>may be considered in women &gt;65 years with a history of current/past smoking.</li> </ul>	IIb	U	





# Correction of CVRF ++++

(80% of aneurysm do not die from aneurysm)



Reduction in aneurysm rupture (7 à 8000 death/year in France ) **Programmed** intervention

13 000 aneuryms repaired in France each years (HAS)







SFMV set up a year of national screening for AAA (Vesalius operation November 2014 to November 2015) in order to increase public and physician awareness about AAA detection, therapeutic management, and monitoring.

HOSPITAL, PRIVATE PRACTICE, during one year for each patient which are examined by a Vascular Physician regardless of the reason for consultation.

We use SFMV criteria.

FREE B MODE SCREENING (less 1 MINUTE)






#### **Number of persons examined**

Prevalence AAA	Number
1%	72 900
2%	36 500
3%	24 300
4%	18 200
5%	14 200





#### **Population**





**Sex RATIO W/M = 1/5** 



# Abdominal aortic aneurysms in women

Ruby C. Lo, MD, and Marc L. Schermerhorn, MD, Boston, Mass

Abdominal aortic aneurysm (AAA) has long been recognized as a condition predominantly affecting males, with sexassociated differences described for almost every aspect of the disease from pathophysiology and epidemiology to morbidity and mortality. Women are generally spared from AAA formation by the immunomodulating effects of estrogen, but once they develop, the natural history of AAAs in women appears to be more aggressive, with more rapid expansion, a higher tendency to rupture at smaller diameters, and higher mortality following rupture. However, simply repairing AAAs at smaller diameters in women is a debatable solution, as even elective endovascular AAA repair is fraught with higher morbidity and mortality in women compared to men. The goal of this review is to summarize what is currently known about the effect of gender on AAA presentation, treatment, and outcomes. Additionally, we aim to review current controversies over screening recommendations and threshold for repair in women. (J Vasc Surg 2016;63:839-44.)

Screening: WOMEN ≥ 65 years : aneurysm rate> men of the same age who have never smoked or with family history

Expansion, rupture, surgical risk> men





## **Population**

50 / 65 years old	28%
66 to 75 years old	37%
> 75 ans (90*)	35% ( 80% between
	75 to 85 ans)



Age Average FEMALES: 68 ans


**MEN** : 75 ans







- Fumeur actif (211)
- Ancien fumeur (377)
- N'a jamais fumé (141)







# 729 AAA déte Without men < 65 years old, 25 men died Without female detection, 124 Aneurysm lost, and 28 died Respect of HAS rules: 53 persons died! > 7

74%

MEN and FEMALE M anf F > 60 years old (SFMV) , > M > 65 years old (HAS)



#### Diameter

Diameter	%	
30 - 39 mm (DAP moy = 35mm)	61 % (n = 444)	
40 - 45 mm (DAP moy = 43 mm)	15,5% (n = 113)	82,8%
46 - 49 mm (DAP moy =47 mm)	6,3 % (n =46)	
≥ 50 mm (DAP moy = 58 mm)	17,2% (n = 126)	17,2%

30 mm < DAP < 100 mm



Mean DAP::43 mm

1 aneurysm out of 6:50 mm of diameter





# Number of patients to be screened for 1 aneurysm from our population

Estimated prevalence aneurysm, patients numbrer	30 mm ≤ A ≤ 49 mm (82%)	≥ 50 mm (18%)
1% (72 900)	120	578
2% (36 500)	60	289
3% (24 300)	40	192
4% (18 200)	30	144
5% (14 200)	23	112



### **Conclusion 1**

- WE demonstrate our capacity to perform aneurysm screening
- Screening female > 65 years old and tobacco consumers will be instituted (as opposed to HAS recommendations)
- Need to follow SFMV recommendations
- 1 patient targeted out of 120 has an AAA ≥ 30 mm and 1 out of 578 an AAA ≥ 50 mm, 1 aneurysm out of 6 = 50 mm
- Our results will be communicated to the HAS (current article)
- This screening must be institutionalized by all vascular doctors, every day but also for all ultrasound examination (targeted population)
- QUESTION: real impact correction RCVF in case of aneurysm



# YES, WE SAVE LIFE!



# **Conclusion 2**

Journal des Maladies Vasculaires (Paris)
© 2006. Elsevier Masson SAS. Tous droits réservés. 31, 5, 260-276

#### RECOMMANDATION

DÉPISTAGE DES ANÉVRYSMES DE L'AORTE ABDOMINALE ET SURVEILLANCE DES PETITS ANÉVRYSMES DE L'AORTE ABDOMINALE : ARGUMENTAIRE ET RECOMMANDATIONS DE LA SOCIÉTÉ FRANÇAISE DE MÉDECINE VASCULAIRE

#### Rapport final

« The success of a screening program largely depends on how patients are managed after the screening test. ... Of great concern for patients with small AAAs detected at screening is the risk of unnecessary procedures. » F.A. LEDERLE (ADAM study), Ann Intern Med 2003; 139: 516-22(1).



